IGF::OT::IGF HTS TO IDENTIFY INHIBITORS OR HIV-1 VPU

IGF::OT::IGF HTS 用于识别抑制剂或 HIV-1 VPU

• 批准号: 9363261
• 负责人: ROGER PTAK
• 金额: $ 77.66万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-15 至 2018-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9363261
• 关键词: Academia; Biochemical; Biological Assay; Cells; Chemicals; Contracts; Data; Development; Funding; Gene Expression; HIV; HIV Infections; HIV-1; Investigational New Drug Application; Libraries; Local Microbicides; National Institute of Allergy and Infectious Disease; Private Sector; Public Health; Research Personnel; Services; Source; Testing; Therapeutic; base; high throughput screening; inhibitor/antagonist; novel therapeutics; phase I trial; pre-clinical; product development; prospective; public health priorities

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications. Interventional agents are tested in confirmatory and specialized assays in high-throughput format (i.e., greater than 96-well plates) with the objective of identifying and characterizing agents that block HIV infection, inhibit HIV gene expression and replication, and/or cure infected cells of HIV infection. Inhibitors of HIV Vpu will be targeted.

针对艾滋病毒的新疗法和局部杀微生物剂的开发和采用仍然是公共卫生的高度优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界、私营部门或其他来源的有前途的治疗性和局部杀微生物剂候选药物的临床前开发。该合同以标准和高通量筛选（HTS）格式提供利用生化和基于细胞的测定的产品开发服务。根据该合同提供的服务将帮助各种各样的研究人员获得获得额外资金所需的关键数据，获得潜在的合作伙伴关系（无论是进一步开发还是支持I期试验），并满足监管机构对研究性新药（IND）申请的要求。在高通量格式（即大于96孔板）的验证性和专门分析中对介入性药物进行测试，目的是识别和表征阻断HIV感染、抑制HIV基因表达和复制和/或治愈HIV感染感染细胞的药物。HIV Vpu抑制剂将成为靶标。